Mepolizumab does not alter levels of eosinophils, T cells, and mast cells in the duodenal mucosa in eosinophilic esophagitis

J Allergy Clin Immunol. 2010 Jul;126(1):175-7. doi: 10.1016/j.jaci.2010.04.029. Epub 2010 Jun 12.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Duodenum / pathology*
  • Eosinophilia / drug therapy*
  • Eosinophilia / immunology
  • Eosinophils / drug effects*
  • Esophagitis / drug therapy*
  • Esophagitis / immunology
  • Female
  • Humans
  • Interleukin-5 / antagonists & inhibitors*
  • Intestinal Mucosa / pathology*
  • Male
  • Mast Cells / drug effects*
  • T-Lymphocytes / drug effects*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Interleukin-5
  • mepolizumab

Associated data

  • ClinicalTrials.gov/NCT00274703